References
- Shah N, Cabanillas F, McIntyre B, . Prognostic value of serum CD44, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 levels in patients with indolent non-Hodgkin lymphomas. Leuk Lymphoma. 2012;53:50–56.
- Solal-Celigny P, Roy P, Colombat P, . Follicular Lymphoma International Prognostic Index. Blood 2004;104:1258–1265.
- Montoto S, Lopez-Guillermo A, Altes A, . Predictive value of Follicular Lymphoma International Prognostic Index (FLIPI) in patients with follicular lymphoma at first progression. Ann Oncol 2004;15:1484–1489.
- Buske C, Hoster E, Dreyling M, . The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood 2006;108:1504–1508.
- Federico M, Bellei M, Marcheselli L, . Follicular Lymphoma International Prognostic Index 2: a new prognostic index for follicular lymphoma developed by the International Follicular Lymphoma Prognostic Factor Project. J Clin Oncol 2009;27:4555–4562.
- Martin A, Weisenburger D, Chan W, . Prognostic value of cellular proliferation and histologic grade in follicular lymphoma. Blood 1995;85:3671–3678.
- Farinha P, Masoudi H, Skinnider BF, . Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood 2005;106:2169–2174.
- Dave SS, Wright G, Tan B, . Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004;351:2159–2169.